News Releases

Study Designed to Evaluate the Use of Apixaban in On-X Aortic Valve Patients ATLANTA , Dec. 23, 2019 /PRNewswire/ --  CryoLife, Inc. (NYSE: CRY) , a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has received authorization from the U.S.

CryoLife Will Supply NeoPatch, a Chorioamniotic Membrane Tissue, to Misonix ATLANTA , Dec. 19, 2019 /PRNewswire/ --   CryoLife, Inc. (" CryoLife "; NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has entered into an agreement whereby

Product Launch Anticipated in the First Quarter 2020 ATLANTA , Dec. 2, 2019 /PRNewswire/ --   CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today it has received CE Mark for the E-nya thoracic stent graft system for the minimally

First Off-the-Shelf Thoraco-abdominal Stent Graft with Pre-Cannulated Inner Branch Technology ATLANTA , Dec. 2, 2019 /PRNewswire/ --  CryoLife, Inc. (NYSE: CRY),   a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has received CE Mark for the E-nside

ATLANTA , Oct. 30, 2019 /PRNewswire/ -- Third Quarter and Recent Business Highlights: Total revenues were $67.9 million in the third quarter of 2019, reflecting year over year growth of 5% and a 6% increase on a non-GAAP constant currency basis, both compared to the third quarter of 2018 On-X ®

ATLANTA , Oct. 16, 2019 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2019 third quarter financial results will be released on Wednesday, October 30, 2019 after the market closes.

ATLANTA , Sept. 18, 2019 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in a fireside chat with analysts and investors at the upcoming Deutsche Bank 27 th Annual Leveraged Finance

Positions the Company for Accelerating Revenue and Non-GAAP Earnings Growth Over the Next Five Years Conference Call and Webcast Tomorrow, September 12, 2019 at 8:00 a.m. ET ATLANTA , Sept. 11, 2019 /PRNewswire/ --  CryoLife, Inc. (" CryoLife "; NYSE: CRY), a leading cardiac and vascular surgery

ATLANTA , Aug. 29, 2019 /PRNewswire/ --  CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in two upcoming investor conferences. CryoLife's management will be presenting at the Morgan Stanley 17th Annual

ATLANTA , July 30, 2019 /PRNewswire/ --  Second Quarter and Recent Business Highlights: Total revenues were $71.1 million in the second quarter of 2019, reflecting year over year growth of 4% and a 7% increase on a non-GAAP constant currency basis, both compared to the second quarter of 2018